151
Participants
Start Date
October 28, 2020
Primary Completion Date
July 25, 2022
Study Completion Date
September 7, 2022
ApTOLL
ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
Placebo
White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
Centre Hospitalier Régional Universitaire de Lille, Lille
Foundation Adolphe de Rothschild, Paris
Centre Hospitalier Universitaire de Toulouse, Toulouse
Universitätsklinikum Essen, Essen
Hospital Universitario A Coruña, A Coruña
Hospital Universitario Central de Asturias, Asturias
Hospital Bellvitge, Barcelona
Hospital Germans Trias i Pujol, Barcelona
Hospital Universitario Vall d´Hebron, Barcelona
Hospital Universitario de Gerona Dr. Josep Trueta, Girona
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Princesa, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Virgen del Rocío, Seville
Hospital Universitario y Politécnico La Fe, Valencia
Hospital Clínico Valladolid, Valladolid
Collaborators (1)
Ministry of Science and Innovation, Spain
OTHER_GOV
Anagram
UNKNOWN
aptaTargets S.L.
INDUSTRY